EGFR and glioblastoma: Genetic alterations, including amplification, rearrangement, altered splicing, and mutations, that regulate EGFR expression levels and protein activities in GBM and HNSCC, will eventually lead to the development of resistance toward EGFR inhibitors (108, 110).